Innovent Biologics, Inc. (HKG:1801)
89.70
+3.35 (3.88%)
Jul 10, 2026, 4:08 PM HKT
Innovent Biologics Employees
Innovent Biologics had 7,502 employees as of December 31, 2025. The number of employees increased by 1,843 or 32.57% compared to the previous year.
Employees
7,502
Change
1,843
Growth
32.57%
Revenue / Employee
1.93M HKD
Profits / Employee
120.68K HKD
Market Cap
156.16B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 7,502 | 1,843 | 32.57% |
| Jun 30, 2025 | 6,190 | - | - |
| Dec 31, 2024 | 5,659 | 787 | 16.15% |
| Dec 31, 2023 | 4,872 | -422 | -7.97% |
| Dec 31, 2022 | 5,294 | -274 | -4.92% |
| Dec 31, 2021 | 5,568 | 2,289 | 69.81% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sino Biopharmaceutical | 21,435 |
| WuXi Biologics | 13,252 |
| BeOne Medicines AG | 12,000 |
| 3SBio | 6,109 |
| Shanghai Henlius Biotech | 3,762 |
| Akeso | 3,761 |
| RemeGen | 3,048 |
| Shanghai Junshi Biosciences | 2,903 |
Innovent Biologics News
- 10 days ago - Eli Lilly Hands China Sales Rights for Verzenio to Innovent - GuruFocus
- 11 days ago - Innovent And Lilly Join Forces To Broaden Verzenios Reach In China - Nasdaq
- 11 days ago - Innovent Biologics, Eli Lilly enters Verzen distribution and promotion agreement - TheFly
- 11 days ago - Innovent Biologics (IVBIY) Partners with Eli Lilly for Verzenios® Distribution in China - GuruFocus
- 11 days ago - China's Innovent Biologics gains commercialization rights for Eli Lilly breast cancer drug - Reuters
- 12 days ago - Pfizer, Innovent GLP-1 drugs pass China insurance preliminary review - Reuters
- 16 days ago - Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of IBI324 (OLN324) in DME and Wet AMD; Studies Commencing in Second Half of 2026 - PRNewsWire
- 19 days ago - Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treatment of Multiple Myeloma - PRNewsWire